Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
25 janv. 2018 09h00 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical...